Drug maker Zydus Lifesciences Ltd on Tuesday (December 9) said its wholly-owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates, has entered into a strategic partnership with Formycon AG for the exclusive licensing and supply of FYB206, a biosimilar of Keytruda (pembrolizumab), in the United States and Canada.

Under the terms of the agreement, Formycon AG will be responsible for the development, registration, manufacture and supply of the product. Zydus Lifesciences Global FZE, UAE, will handle the commercialisation of FYB206 in the defined territories of the USA and Canada.

The company said the biologics licence application is expected to be submitted to the US Food and Drug Administration in the near future. The partnership is aimed at making immunotherapy affordabl

See Full Page